Lombard's H1 "in line" as US Aorfix launch picks up pace
This article was originally published in Clinica
Executive Summary
Lombard Medical Technologies’ first-half revenues grew 2% year-on-year to £2.0m ($3.1m), “in line” with Canaccord Genuity analyst Julie Simmonds’ expectations and its previous trading update in July. The firm’s US launch of its flagship Aorfix stent for abdominal aortic aneurysms (AAA) is “well underway” CEO Simon Hubbert told Clinica – the device got the FDA go-ahead in February for use in patients with high-angle aneurysms of up to 90 degrees (www.clinica.co.uk, 18 February 2013).